- Home
- NCPL vs CNSP Comparison
NCPL vs CNSP Comparison
Compare NCPL & CNSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NCPL | CNSP |
|---|---|---|
| Founded | 1984 | 2017 |
| Country | United States | United States |
| Employees | 20 | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1M | 7.3M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | NCPL | CNSP |
|---|---|---|
| Price | $0.70 | $4.53 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | ★ 7.4M | 25.6K |
| Earning Date | 03-19-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 8.03 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $739.37 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.31 | $0.73 |
| 52 Week High | $8.75 | $10.59 |
Technical Indicators
Market Signals| Indicator | NCPL | CNSP |
|---|---|---|
| Relative Strength Index (RSI) | 46.11 | 48.52 |
| Support Level | $0.59 | $4.50 |
| Resistance Level | $0.84 | $5.61 |
| Average True Range (ATR) | 0.13 | 0.31 |
| MACD | -0.06 | -0.09 |
| Stochastic Oscillator | 13.35 | 31.83 |
Price Performance
Historical ComparisonAbout NCPL Netcapital Inc.
Netcapital Inc is a financial technology company. The company facilitates the growth of private companies by providing fundraising services and other consulting services. The company's online private investment platform connects entrepreneurs and investors, enabling companies to raise capital digitally. The Company operates in a single operating segment, which is the provision of fintech services.
About CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a biotechnology company focused on developing therapies for serious diseases in neurology and oncology. The company is building a high-value pipeline for neurology and oncology indications. Its new corporate includes pivoting from a singular focus on glioblastoma multiforme and exploring out-licensing opportunities for its legacy assets, TPI 287 and Berubicin.